OPPERBAS HOLDING IN BREAKTHROUGH CLINICAL STUDY.

(Full text of a statement, contact details below)

BRUSSELS & STOCKHOLM, June 1 /PRNewswire-AsiaNet/ -- Opperbas Holding B.V. is conducting a phase II clinical trial using its proprietary PEGylated liposomes to prolong the half-life and hemostatic efficacy of recombinant factor VIII, a protein used to treat haemophilia A, a technology developed for Opperbas by the Israeli-based Omri Laboratories Ltd. research company. The delivery technology showed very encouraging results in the phase I/II trial completed last year.

Hemophilia A is currently treated by up to three weekly infusions of FVIII, a protein that is lacking or defective in the affected patients. Opperbas' technology as developed by Omri, carries the potential of reducing the number of infusions to a third of what is presently used while retaining clinical efficacy. This may lead to a major improvement in patient convenience and treatment modality, enabling more patients to use prophylactic treatment and preventing painful and disabling bleeding episodes.

"We are very pleased with the outcomes so far," says Dr. Jack Spira, Medical Director. "Our technology has shown to be very promising and we are currently looking at other diseases in which a similar approach can be utilized to enhance the efficacy of protein/peptide drugs."

"Our goal is to out-license this first indication to one of the major haemophilia ...